Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
HLYK Stock Summary
In the News
HealthLynked revamps app to emphasize smooth communication between patients and healthcare providers
HealthLynked (OTCQB:HLYK) Corp said it is rolling out major updates to its HealthLynked (OTCQB:HLYK) app. The updates are each meant to streamline communication between users and their healthcare providers, according to a statement, while also ensuring the utmost security.
HealthLynked taps Bill Crupi as regional manager of healthcare services as it eyes growth
HealthLynked (OTCQB:HLYK) Corp named Bill Crupi, who has a track record of successfully managing medical facilities and maintaining compliance standards, as the regional manager of healthcare services, as the company eyes rapid growth. The Naples, Florida-based healthcare network company noted that Crupi brings with him “a wealth of experience” in operations management, human resources operations, IT management, accounting, and financial planning.
HealthLynked swings to a profit in 1Q; sees revenue grow
HealthLynked (OTCQB:HLYK), a provider of healthcare technologies, swung to a profit in the first quarter of 2023 following the divestment of ACO Health Partners in January. For the three months ended March 31, the company posted a profit of $1.45 million which the company noted was “a significant turnaround” from a loss of $1.17 million in the year-ago quarter.
HealthLynked strikes deal to sell ACO Health Partners for up to $3M in cash and $7M in IPO shares of PBACO
HealthLynked (OTCQB:HLYK) Corp revealed that it has signed a definitive agreement to sell its ACO Health Partners (AHP) subsidiary to PBACO Holding LLC (PBA), which does business as Palm Beach Accountable Care Organization (PBACO) in a cash-and-stock deal. In a statement, HealthLynked (OTCQB:HLYK) founder CEO Dr Michael Dent said: "We are thrilled to be working with such a like-minded group that prioritizes physician efficiency and high-quality patient care.
HealthLynked Corp launches concierge membership program
HealthLynked (OTCQB:HLYK) Corp said its Naples Center for Functional Medicine has implemented a Concierge medical membership program for patients to provide better access, more time with physicians, and connectivity to HealthLynked (OTCQB:HLYK)'s online patient concierge services. With strong initial adoption from patients, the program is estimated to generate over $1 million in incremental annual revenue, the global healthcare network company said.
HealthLynked reports annual revenue growth of 50% to $9.2M
HealthLynked (OTCQB:HLYK) Corp has announced a strong rise in full-year 2021 revenue, supported by growth at its ACO and Management Service Organizations (MSO) divisions. The company reported revenue of $9.2 million for the year to December 31, 2021, up 50% from the prior year.
HealthLynked announces updated version of Oohvie, its App for women's health
HealthLynked (OTCQB:HLYK) Corp has announced an updated version of Oohvie, its App for women's health that tracks menstrual cycles and other changes associated with ovulation. Oohvie was released in November 2020 and currently has over 30,000 downloads.
US indices mixed after weekly labour market report
12:05pm: Wall Street mixed US stocks were mixed at the midday point as investors mulled fresh data on the labour market and inflation. At noon, the Dow Jones Industrial Average continued to climb, gaining 188 points, or 0.5% at 36,472 points, while the broader S&P 500 and tech-laden stock index Nasdaq Composite both dropped by 0.1% and 0.7%, respectively.
US indices mix after weekly labour market report
12:05pm: Wall Street mixed US stocks were mixed at the midday point as investors turned to fresh data on the labour market and inflation report on Wednesday. At noon, the Dow Jones Industrial Average continued to climb, gaining 188 points, or 0.5% at 36,472 points, while the broader S&P 500 and tech-laden stock index Nasdaq Composite both dropped by 0.1% and 0.7%, respectively.
HealthLynked sees its 3Q revenue climb 98% to $4M on strong patient volume
HealthLynked (OTCQB:HLYK) Corp has announced third-quarter 2021 revenue of $4.0 million, a 98% year-over-year increase, as patient appointments rose 24%. The company also said its Health Services division's foundational patient services revenue increased 32% in 3Q, compared to a 10% decrease during the same period last year.
HLYK Financial details
HLYK Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.03 | 0.04 | 0.04 | 0.04 | 0.02 | |
Net income per share | -0.07 | -0.14 | -0.04 | -0.05 | -0.04 | |
Operating cash flow per share | -0.03 | -0.02 | -0.01 | -0.02 | -0.02 | |
Free cash flow per share | -0.03 | -0.02 | -0.01 | -0.02 | -0.02 | |
Cash per share | 0 | 0 | 0 | 0.01 | 0 | |
Book value per share | -0.04 | -0.03 | 0.01 | 0.03 | 0 | |
Tangible book value per share | -0.04 | -0.04 | -0.04 | 0.01 | 0 | |
Share holders equity per share | -0.04 | -0.03 | 0.01 | 0.03 | 0 | |
Interest debt per share | 0.03 | 0.04 | 0.03 | 0 | 0.01 | |
Market cap | 10.64M | 13.87M | 16.1M | 104.35M | 16.67M | |
Enterprise value | 12.24M | 16.33M | 18.83M | 102.04M | 17.9M | |
P/E ratio | -1.84 | -0.97 | -2.62 | -10.02 | -1.89 | |
Price to sales ratio | 4.71 | 3.45 | 2.62 | 11.34 | 2.85 | |
POCF ratio | -4.52 | -5.87 | -7.6 | -27.68 | -3.82 | |
PFCF ratio | -4.51 | -5.84 | -7.51 | -27.54 | -3.8 | |
P/B Ratio | -3.63 | -4.88 | 11.92 | 14.49 | 53.03 | |
PTB ratio | -3.63 | -4.88 | 11.92 | 14.49 | 53.03 | |
EV to sales | 5.42 | 4.06 | 3.07 | 11.09 | 3.05 | |
Enterprise value over EBITDA | -2.84 | 4.06 | -5.87 | -24.09 | -3.45 | |
EV to operating cash flow | -5.2 | -6.91 | -8.89 | -27.07 | -4.1 | |
EV to free cash flow | -5.19 | -6.88 | -8.79 | -26.93 | -4.08 | |
Earnings yield | -0.54 | -1.03 | -0.38 | -0.1 | -0.53 | |
Free cash flow yield | -0.22 | -0.17 | -0.13 | -0.04 | -0.26 | |
Debt to equity | -0.59 | -0.9 | 2.14 | 0.14 | 4.08 | |
Debt to assets | 4.07 | 1.01 | 0.36 | 0.09 | 0.28 | |
Net debt to EBITDA | -0.37 | 0.61 | -0.85 | 0.55 | -0.24 | |
Current ratio | 0.11 | 0.08 | 0.08 | 1.9 | 0.62 | |
Interest coverage | -3.11 | 2.62 | -3.93 | -263.44 | -75.71 | |
Income quality | 0.41 | 0.43 | 0.37 | 0.36 | 0.54 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 2.31 | 1.32 | 0.92 | 0.87 | 1.35 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0.53 | 0.84 | 0.56 | 0.31 | |
Capex to operating cash flow | 0 | 0 | 0.01 | 0.01 | 0.01 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -0.13 | -0.14 | -0.1 | -0.02 | -0.03 | |
Stock based compensation to revenue | 0.21 | 0.13 | 0.09 | 0.08 | 0.08 | |
Graham number | 0.25 | 0.31 | 0.1 | 0.19 | 0.03 | |
ROIC | 2.75 | 1.39K | -0.7 | -0.58 | -3.02 | |
Return on tangible assets | -13.55 | -11.84 | -4.82 | -2.23 | -2.8 | |
Graham Net | -0.04 | -0.05 | -0.04 | 0 | -0.02 | |
Working capital | -2.98M | -4.91M | -4.48M | 1.73M | -1.33M | |
Tangible asset value | -2.93M | -4.18M | -5.4M | 1.18M | -1.12M | |
Net current asset value | -2.99M | -4.99M | -6.27M | 159.83K | -2.12M | |
Invested capital | -0.59 | -0.9 | 2.14 | 0.14 | 4.08 | |
Average receivables | 114.12K | 99.07K | 85.2K | 86.72K | 214.15K | |
Average payables | 323.92K | 615.4K | 1.36M | 1.1M | 584.94K | |
Average inventory | 48.01K | 83.24K | 82.83K | 115.07K | 163.88K | |
Days sales outstanding | 18.56 | 7.56 | 5.19 | 3.42 | 21.31 | |
Days payables outstanding | 60.82 | 72.02 | 593.23 | 37.01 | 680.63 | |
Days of inventory on hand | 14.81 | 6.07 | 29.85 | 16.31 | 151.97 | |
Receivables turnover | 19.66 | 48.27 | 70.37 | 106.6 | 17.13 | |
Payables turnover | 6 | 5.07 | 0.62 | 9.86 | 0.54 | |
Inventory turnover | 24.65 | 60.16 | 12.23 | 22.38 | 2.4 | |
ROE | 1.97 | 5.04 | -4.56 | -1.45 | -28.04 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.01 | 0 | 0.01 | 0.01 | 0.01 | |
Net income per share | -0.01 | -0.02 | 0.01 | 0 | 0 | |
Operating cash flow per share | -0.01 | 0 | 0 | 0 | 0 | |
Free cash flow per share | -0.01 | 0 | 0 | 0 | 0 | |
Cash per share | 0 | 0 | 0 | 0 | 0 | |
Book value per share | 0.02 | 0 | 0.01 | 0.01 | 0.01 | |
Tangible book value per share | -0.01 | 0 | 0 | 0 | 0 | |
Share holders equity per share | 0.02 | 0 | 0.01 | 0.01 | 0.01 | |
Interest debt per share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Market cap | 17.81M | 16.67M | 20.57M | 18.07M | 12.85M | |
Enterprise value | 19.14M | 17.9M | 22.31M | 19.01M | 14.91M | |
P/E ratio | -2.49 | -0.98 | 3.54 | -4.5 | -18.37 | |
Price to sales ratio | 12.3 | 14.44 | 11.72 | 10.61 | 9.64 | |
POCF ratio | -14.31 | -27.77 | -18.71 | -29.93 | -10.29 | |
PFCF ratio | -14.31 | -26.72 | -18.71 | -29.93 | -10.27 | |
P/B Ratio | 4.41 | 53.03 | 9.49 | 11.49 | 8.23 | |
PTB ratio | 4.41 | 53.03 | 9.49 | 11.49 | 8.23 | |
EV to sales | 13.22 | 15.49 | 12.71 | 11.16 | 11.19 | |
Enterprise value over EBITDA | -11.39 | -27.73 | -23.04 | -27.35 | -21.77 | |
EV to operating cash flow | -15.38 | -29.81 | -20.29 | -31.48 | -11.93 | |
EV to free cash flow | -15.38 | -28.68 | -20.29 | -31.48 | -11.92 | |
Earnings yield | -0.1 | -0.26 | 0.07 | -0.06 | -0.01 | |
Free cash flow yield | -0.07 | -0.04 | -0.05 | -0.03 | -0.1 | |
Debt to equity | 0.37 | 4.08 | 0.83 | 1.18 | 1.35 | |
Debt to assets | 0.2 | 0.28 | 0.29 | 0.34 | 0.37 | |
Net debt to EBITDA | -0.79 | -1.89 | -1.8 | -1.35 | -3 | |
Current ratio | 0.2 | 0.62 | 0.68 | 0.54 | 0.66 | |
Interest coverage | -66.79 | -20.33 | -14.14 | -4.76 | -7.91 | |
Income quality | 0.7 | 0.17 | -0.73 | 0.61 | 7.74 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 1.31 | 1.64 | 1.18 | 1.02 | 1.16 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0.78 | 0.31 | 0.22 | 0.24 | 0.17 | |
Capex to operating cash flow | 0 | 0.04 | 0 | 0 | 0 | |
Capex to revenue | 0 | -0.02 | 0 | 0 | 0 | |
Capex to depreciation | 0 | -0.11 | 0 | 0 | -0.02 | |
Stock based compensation to revenue | 0.04 | 0.1 | 0.05 | 0.05 | 0.04 | |
Graham number | 0.05 | 0.02 | 0.03 | 0.02 | 0.01 | |
ROIC | -0.29 | -0.48 | 0.29 | -0.25 | -0.31 | |
Return on tangible assets | -1.07 | -1.36 | 0.3 | -0.24 | -0.04 | |
Graham Net | -0.01 | -0.02 | -0.01 | -0.01 | -0.01 | |
Working capital | -1.99M | -1.33M | -1.07M | -1.53M | -1.16M | |
Tangible asset value | -1.78M | -1.12M | 793.72K | 253.94K | 620.01K | |
Net current asset value | -2.94M | -2.12M | -1.74M | -2.16M | -1.93M | |
Invested capital | 0.37 | 4.08 | 0.83 | 1.18 | 1.35 | |
Average receivables | 76.97K | 202.94K | 1.12M | 1.26M | 1.28M | |
Average payables | 586.16K | 756.42K | 879.55K | 877.87K | 746.47K | |
Average inventory | 185.74K | 190.69K | 192.88K | 174.69K | 149.36K | |
Days sales outstanding | 3.97 | 26.65 | 96.99 | 32.87 | 130.36 | |
Days payables outstanding | 137.37 | 75.09 | 2.51K | 2.25K | 1.39K | |
Days of inventory on hand | 39.9 | 16.76 | 541.6 | 409.37 | 313.64 | |
Receivables turnover | 22.67 | 3.38 | 0.93 | 2.74 | 0.69 | |
Payables turnover | 0.66 | 1.2 | 0.04 | 0.04 | 0.06 | |
Inventory turnover | 2.26 | 5.37 | 0.17 | 0.22 | 0.29 | |
ROE | -0.44 | -13.59 | 0.67 | -0.64 | -0.11 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
HLYK Frequently Asked Questions
What is HealthLynked Corp. stock symbol ?
HealthLynked Corp. is a US stock , located in Naples of Fl and trading under the symbol HLYK
What is HealthLynked Corp. stock quote today ?
HealthLynked Corp. stock price is $0.0569 today.
Is HealthLynked Corp. stock public?
Yes, HealthLynked Corp. is a publicly traded company.